US 11,806,354 B2
Pharmaceutical compositions comprising meloxicam
Herriot Tabuteau, New York, NY (US)
Assigned to AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed by AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed on Sep. 2, 2022, as Appl. No. 17/929,633.
Application 17/929,633 is a continuation in part of application No. 17/549,081, filed on Dec. 13, 2021, granted, now 11,433,079.
Application 17/549,081 is a continuation in part of application No. PCT/US2021/026027, filed on Apr. 6, 2021.
Application 17/549,081 is a continuation in part of application No. 17/145,744, filed on Jan. 11, 2021, granted, now 11,207,327, issued on Dec. 28, 2021.
Application 17/145,744 is a continuation in part of application No. 16/854,320, filed on Apr. 21, 2020, granted, now 10,894,053, issued on Jan. 19, 2021.
Application PCT/US2021/026027 is a continuation in part of application No. 16/842,063, filed on Apr. 7, 2020, granted, now 10,799,588, issued on Oct. 13, 2020.
Application 16/842,063 is a continuation of application No. 16/867,929, filed on May 6, 2020, granted, now 10,821,182, issued on Nov. 3, 2020.
Application 16/867,929 is a continuation of application No. 16/841,436, filed on Apr. 6, 2020, granted, now 10,821,181, issued on Nov. 3, 2020.
Application 16/854,320 is a continuation in part of application No. 16/570,451, filed on Sep. 13, 2019, granted, now 10,729,697, issued on Aug. 4, 2020.
Application 16/570,451 is a continuation in part of application No. 16/001,697, filed on Jun. 6, 2018, granted, now 10,471,014, issued on Nov. 12, 2019.
Application 16/001,697 is a continuation in part of application No. 15/976,800, filed on May 10, 2018, granted, now 10,471,068, issued on Nov. 12, 2019.
Application 15/976,800 is a continuation in part of application No. PCT/US2018/012433, filed on Jan. 4, 2018.
Claims priority of provisional application 63/006,023, filed on Apr. 6, 2020.
Claims priority of provisional application 62/680,956, filed on Jun. 5, 2018.
Claims priority of provisional application 62/536,466, filed on Jul. 25, 2017.
Claims priority of provisional application 62/504,105, filed on May 10, 2017.
Claims priority of provisional application 62/442,136, filed on Jan. 4, 2017.
Prior Publication US 2023/0000880 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5415 (2006.01); A61K 9/00 (2006.01); A61K 31/4196 (2006.01); A61P 25/06 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/5415 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 31/4196 (2013.01); A61P 25/06 (2018.01)] 16 Claims
 
1. A method of treating migraine, comprising orally administering one tablet daily to a human being in need thereof, wherein the tablet comprises about 20 mg of meloxicam, or a molar equivalent amount of a salt form of meloxicam, and about 10 mg to about 15 mg of a rizatriptan in a salt form or the free base form, wherein the meloxicam is complexed with a sulfobutyl ether β-cyclodextrin (SBEβCD), wherein the Tmax of meloxicam in the human being is less than 60 minutes, wherein the human being has acute pain, wherein the human being experiences pain relief at about 2 hours after the tablet is orally administered, and wherein administration of the tablet achieves a reduction in pain that lasts at least about 24 hours.